Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxcyte Inc (NQ: PCVX )

114.27 +1.13 (+1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte Inc

< Previous 1 2 3 4 5 Next >
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Peering Into Vaxcyte's Recent Short Interest
Via Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Recap: Vaxcyte Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... 
Via Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. 
Via Investor's Business Daily
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Appoints John Furey to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Pricing of $750 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Appoints Whitney Jones as Chief People Officer
From Vaxcyte, Inc.
Via GlobeNewswire
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.